January 9, 2018 / 4:30 PM / Updated 39 minutes ago BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019 Reuters Staff 
Jan 9 (Reuters) - Bluebird Bio Inc: 
* BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019 
* BLUEBIRD SEES FILING FOR APPROVAL IN BETA THALASSEMIA IN 2018 
* BLUEBIRD BIO SEES FILING FOR US AND EU APPROVAL OF B2121 FOR MULTIPLE MYELOMA IN 2019 Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)